August 10, 2020
Article
A small study out of Sweden adds to context to the puzzle of how best to treat patients with multiple myeloma who contract COVID-19.
August 07, 2020
Article
Yale New Haven Hospital’s reorganization of its sickle cell disease program led patients to report feeling better off and needing fewer hospitalizations. However, the change left some with the disease still feeling unsatisfied.
August 01, 2020
Article
New research suggests white and African American patients have similar rates of access to new treatments for multiple myeloma.
August 01, 2020
Article
A new study finds even if renal function is restored, patients who have severe renal impairment when diagnosed with multiple myeloma have lower overall survival rates.
July 30, 2020
Article
Bristol Myers Squibb and bluebird bio submitted a second Biologics License Application (BLA) to the FDA for idecabtagene vicleucel (ide-cel), the companies’ investigational B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell immunotherapy, indicated for adults with relapsed and refractory multiple myeloma (MM).
July 24, 2020
Article
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
July 24, 2020
Article
A new study may have uncovered reasons why some patients with multiple myeloma have poor outcomes following allogeneic stem cell transplantation.
July 23, 2020
Article
According to the study, vaporized cannabis, when compared with placebo, could be a safe and potentially effective way to address pain linked with sickle cell disease. While the decreases in pain were not statistically significant, the drug did significantly decrease pain interference in mood over a 5-day inpatient stay.
July 22, 2020
Article
During ASCO, Janssen presented results from the CHRYSALIS study on amivantimab, a bispecific antibody being developed to treat non–small cell lung cancer (NSCLC). The pharma giant, along with its parent company, Johnson & Johnson (J&J), had previously received a breakthrough therapy designation in December for teclistamab, another bispecific antibody indicated for potential treatment of multiple myeloma.
July 18, 2020
Article
Only about one-third of patients with multiple myeloma who experience a very good partial response to therapy following first relapse, according to a new study.